Aberrant transforming growth factor-β activation recruits Mesenchymal stem cells during prostatic hyperplasia

Long Wang, Liang Xie, Francis Tintani, Hui Xie, Changjun Li, Zhuang Cui, Mei Wan, Xiongbing Zu, Lin Qi, Xu Cao

Research output: Contribution to journalArticle

Abstract

Benign prostatic hyperplasia (BPH) is the overgrowth of prostate tissues with high prevalence in older men. BPH pathogenesis is not completely understood, but it is believed to be a result of de novo overgrowth of prostatic stroma. In this study, we show that aberrant activation of transforming growth factor-β(TGF-β)mobilizes mesenchymal/stromal stem cells (MSCs) in circulating blood, which are recruited for the prostatic stromal hyperplasia. Elevated levels of active TGF-β were observed in both a phenylephrine-induced prostatic hyperplasia mouse model and human BPH tissues. Nestin lineage tracing revealed that 39.6% ± 6.3% of fibroblasts and 73.3% ± 4.2% smooth muscle cellswere derived fromnestin+ cells in Nestin-Cre, Rosa26-YFPflox/+ mice. Nestin+ MSCs were increased in the prostatic hyperplasia mice. Our parabiosis experiment demonstrate that nestin+ MSCs were mobilized and recruited to the prostatic stroma of wild-type mice and gave rise to the fibroblasts. Moreover, injection of a TGF-β neutralizing antibody (1D11) inhibits mobilization of MSCs, their recruitment to the prostatic stroma and hyperplasia. Importantly, knockout of TbRII in nestin+ cell lineage ameliorated stromal hyperplasia. Thus, elevated levels of TGF-β-inducedmobilization and recruitment of MSCs to the reactive stroma resulting in overgrowth of prostate tissues in BPH and, thus, inhibition of TGF-β activity could be a potential therapy for BPH.

Original languageEnglish (US)
Pages (from-to)394-404
Number of pages11
JournalStem cells translational medicine
Volume6
Issue number2
DOIs
StatePublished - Feb 1 2017

Fingerprint

Prostatic Hyperplasia
Transforming Growth Factors
Mesenchymal Stromal Cells
Nestin
Prostate
Parabiosis
Fibroblasts
Phenylephrine
Cell Lineage
Neutralizing Antibodies
Hyperplasia
Smooth Muscle
Injections

Keywords

  • Benign prostatic hyperplasia
  • Fibrosis
  • Mesenchymal stem cells
  • Stroma
  • Transforming growth factor-β

ASJC Scopus subject areas

  • Developmental Biology
  • Cell Biology

Cite this

Aberrant transforming growth factor-β activation recruits Mesenchymal stem cells during prostatic hyperplasia. / Wang, Long; Xie, Liang; Tintani, Francis; Xie, Hui; Li, Changjun; Cui, Zhuang; Wan, Mei; Zu, Xiongbing; Qi, Lin; Cao, Xu.

In: Stem cells translational medicine, Vol. 6, No. 2, 01.02.2017, p. 394-404.

Research output: Contribution to journalArticle

Wang, Long ; Xie, Liang ; Tintani, Francis ; Xie, Hui ; Li, Changjun ; Cui, Zhuang ; Wan, Mei ; Zu, Xiongbing ; Qi, Lin ; Cao, Xu. / Aberrant transforming growth factor-β activation recruits Mesenchymal stem cells during prostatic hyperplasia. In: Stem cells translational medicine. 2017 ; Vol. 6, No. 2. pp. 394-404.
@article{5c3d4ae5f1b94dbe9ee311a224cc6e18,
title = "Aberrant transforming growth factor-β activation recruits Mesenchymal stem cells during prostatic hyperplasia",
abstract = "Benign prostatic hyperplasia (BPH) is the overgrowth of prostate tissues with high prevalence in older men. BPH pathogenesis is not completely understood, but it is believed to be a result of de novo overgrowth of prostatic stroma. In this study, we show that aberrant activation of transforming growth factor-β(TGF-β)mobilizes mesenchymal/stromal stem cells (MSCs) in circulating blood, which are recruited for the prostatic stromal hyperplasia. Elevated levels of active TGF-β were observed in both a phenylephrine-induced prostatic hyperplasia mouse model and human BPH tissues. Nestin lineage tracing revealed that 39.6{\%} ± 6.3{\%} of fibroblasts and 73.3{\%} ± 4.2{\%} smooth muscle cellswere derived fromnestin+ cells in Nestin-Cre, Rosa26-YFPflox/+ mice. Nestin+ MSCs were increased in the prostatic hyperplasia mice. Our parabiosis experiment demonstrate that nestin+ MSCs were mobilized and recruited to the prostatic stroma of wild-type mice and gave rise to the fibroblasts. Moreover, injection of a TGF-β neutralizing antibody (1D11) inhibits mobilization of MSCs, their recruitment to the prostatic stroma and hyperplasia. Importantly, knockout of TbRII in nestin+ cell lineage ameliorated stromal hyperplasia. Thus, elevated levels of TGF-β-inducedmobilization and recruitment of MSCs to the reactive stroma resulting in overgrowth of prostate tissues in BPH and, thus, inhibition of TGF-β activity could be a potential therapy for BPH.",
keywords = "Benign prostatic hyperplasia, Fibrosis, Mesenchymal stem cells, Stroma, Transforming growth factor-β",
author = "Long Wang and Liang Xie and Francis Tintani and Hui Xie and Changjun Li and Zhuang Cui and Mei Wan and Xiongbing Zu and Lin Qi and Xu Cao",
year = "2017",
month = "2",
day = "1",
doi = "10.5966/sctm.2015-0411",
language = "English (US)",
volume = "6",
pages = "394--404",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "2",

}

TY - JOUR

T1 - Aberrant transforming growth factor-β activation recruits Mesenchymal stem cells during prostatic hyperplasia

AU - Wang, Long

AU - Xie, Liang

AU - Tintani, Francis

AU - Xie, Hui

AU - Li, Changjun

AU - Cui, Zhuang

AU - Wan, Mei

AU - Zu, Xiongbing

AU - Qi, Lin

AU - Cao, Xu

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Benign prostatic hyperplasia (BPH) is the overgrowth of prostate tissues with high prevalence in older men. BPH pathogenesis is not completely understood, but it is believed to be a result of de novo overgrowth of prostatic stroma. In this study, we show that aberrant activation of transforming growth factor-β(TGF-β)mobilizes mesenchymal/stromal stem cells (MSCs) in circulating blood, which are recruited for the prostatic stromal hyperplasia. Elevated levels of active TGF-β were observed in both a phenylephrine-induced prostatic hyperplasia mouse model and human BPH tissues. Nestin lineage tracing revealed that 39.6% ± 6.3% of fibroblasts and 73.3% ± 4.2% smooth muscle cellswere derived fromnestin+ cells in Nestin-Cre, Rosa26-YFPflox/+ mice. Nestin+ MSCs were increased in the prostatic hyperplasia mice. Our parabiosis experiment demonstrate that nestin+ MSCs were mobilized and recruited to the prostatic stroma of wild-type mice and gave rise to the fibroblasts. Moreover, injection of a TGF-β neutralizing antibody (1D11) inhibits mobilization of MSCs, their recruitment to the prostatic stroma and hyperplasia. Importantly, knockout of TbRII in nestin+ cell lineage ameliorated stromal hyperplasia. Thus, elevated levels of TGF-β-inducedmobilization and recruitment of MSCs to the reactive stroma resulting in overgrowth of prostate tissues in BPH and, thus, inhibition of TGF-β activity could be a potential therapy for BPH.

AB - Benign prostatic hyperplasia (BPH) is the overgrowth of prostate tissues with high prevalence in older men. BPH pathogenesis is not completely understood, but it is believed to be a result of de novo overgrowth of prostatic stroma. In this study, we show that aberrant activation of transforming growth factor-β(TGF-β)mobilizes mesenchymal/stromal stem cells (MSCs) in circulating blood, which are recruited for the prostatic stromal hyperplasia. Elevated levels of active TGF-β were observed in both a phenylephrine-induced prostatic hyperplasia mouse model and human BPH tissues. Nestin lineage tracing revealed that 39.6% ± 6.3% of fibroblasts and 73.3% ± 4.2% smooth muscle cellswere derived fromnestin+ cells in Nestin-Cre, Rosa26-YFPflox/+ mice. Nestin+ MSCs were increased in the prostatic hyperplasia mice. Our parabiosis experiment demonstrate that nestin+ MSCs were mobilized and recruited to the prostatic stroma of wild-type mice and gave rise to the fibroblasts. Moreover, injection of a TGF-β neutralizing antibody (1D11) inhibits mobilization of MSCs, their recruitment to the prostatic stroma and hyperplasia. Importantly, knockout of TbRII in nestin+ cell lineage ameliorated stromal hyperplasia. Thus, elevated levels of TGF-β-inducedmobilization and recruitment of MSCs to the reactive stroma resulting in overgrowth of prostate tissues in BPH and, thus, inhibition of TGF-β activity could be a potential therapy for BPH.

KW - Benign prostatic hyperplasia

KW - Fibrosis

KW - Mesenchymal stem cells

KW - Stroma

KW - Transforming growth factor-β

UR - http://www.scopus.com/inward/record.url?scp=85017608542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017608542&partnerID=8YFLogxK

U2 - 10.5966/sctm.2015-0411

DO - 10.5966/sctm.2015-0411

M3 - Article

C2 - 28191756

AN - SCOPUS:85017608542

VL - 6

SP - 394

EP - 404

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 2

ER -